Vemircopan治疗全身型重症肌无力的疗效与安全性随机临床试验
这项双盲、平行组、安慰剂对照2期随机临床试验纳入70例乙酰胆碱受体抗体阳性全身型重症肌无力成人患者,评估口服选择性因子D抑制剂vemircopan的疗效与安全性。主要终点为8周双盲期内连续4周MG-ADL总分较基线下降≥2分且未使用挽救治疗的比例,结果安慰剂组与vemircopan 180mg组、120mg组均无显著差异,次要终点亦无显著差异,研究因未达到预设疗效阈值而终止。
要点
- Vemircopan 180mg和120mg组主要终点达标比例与安慰剂组无显著差异。
- 次要终点包括MG-ADL、QMG和NDF评分变化均无显著差异。
- 未报告脑膜炎球菌感染,但1例死于肝衰竭、1例因单纯疱疹脑膜炎停药。
核心结论
- Vemircopan未达到预设疗效阈值,研究因此终止。
- 在AChR-Ab+全身型重症肌无力成人患者中,vemircopan 180mg和120mg与安慰剂相比未见显著疗效差异。
研究设计与样本
- 双盲、平行组、安慰剂对照2期随机临床试验,2022年4月14日至2024年4月3日在8个国家60个中心开展。
- 纳入70例AChR-Ab+全身型重症肌无力成人患者,MG-ADL评分≥5且MGFA分级II至IV级。
- 按2:1:2随机分配至口服vemircopan 180mg每日两次、120mg每日两次或安慰剂组。
主要发现
- 主要终点达标比例:安慰剂组18/28(64%;90%CI 47%-79%),vemircopan 180mg组16/28(57%;90%CI 40%-73%),120mg组8/14(57%;90%CI 33%-79%),组间无显著差异。
- 次要终点(MG-ADL总分、QMG总分、NDF问卷评分第8周较基线变化)均无显著差异。
- 未报告脑膜炎球菌感染病例;1例参与者死于肝衰竭,1例因单纯疱疹脑膜炎终止研究治疗。
关键数值与推荐
- 主要终点为8周双盲主要评估期内连续4周MG-ADL总分较基线下降≥2分且未使用挽救治疗的比例。
- 纳入标准包括AChR-Ab+全身型重症肌无力、MG-ADL评分≥5、MGFA分级II至IV级。
临床怎么用
- 当前证据不支持vemircopan用于AChR-Ab+全身型重症肌无力的治疗。
- 针对补体替代途径的口服因子D抑制剂在该人群中未显示优于安慰剂的疗效。
局限性
- 本研究为2期临床试验,样本量较小(共70例随机),各治疗组样本量有限。
- 研究因未达到预设疗效阈值而终止,未进一步评估长期疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Inhibition of terminal complement component 5 has proven effective in acetylcholine receptor antibody-positive (AChR-Ab+) generalized myasthenia gravis (gMG) but requires intravenous or daily subcutaneous administration and is associated with an increased meningococcal infection risk. Targeting the complement alternative pathway (AP) may offer similar benefits while sparing the classical and lectin pathways, preserving some immune responses against infection. OBJECTIVE: To evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of vemircopan, an oral, selective factor D inhibitor that blocks AP-mediated complement activation and amplification, in adults with AChR-Ab+ gMG. DESIGN, SETTING, AND PARTICIPANTS: This double-blind, parallel-group, placebo-controlled phase 2 randomized clinical trial was conducted between April 14, 2022, and April 3, 2024, at 60 sites across 8 countries. Adults with AChR-Ab+ gMG, Myasthenia Gravis-Activities of Daily Living (MG-ADL) score of 5 or greater, and Myasthenia Gravis Foundation of America classes II through IV classification were eligible for inclusion. Data were unblinded in June 2024; final analysis was completed October 2024. INTERVENTION: Randomization 2:1:2 to twice-daily oral vemircopan, 180 mg or 120 mg, or placebo. MAIN OUTCOMES AND MEASURES: The primary end point was the proportion of participants achieving a 2-point or greater reduction in MG-ADL total score from baseline for 4 consecutive weeks, without rescue therapy, during the 8-week, double-blind primary evaluation period. Secondary end points were change from baseline to week 8 in MG-ADL total score, Quantitative Myasthenia Gravis total score, and Neurological Disorders Fatigue questionnaire score. RESULTS: Of 99 individuals screened, 70 met eligibility criteria, and 29 were excluded. Of 70 participants randomized (vemircopan, 180 mg: n = 28; vemircopan, 120 mg: n = 14; placebo: n = 28), 38 participants (54%) were female; mean (SD) age at diagnosis was 45.4 (18.5) years. The proportion of participants achieving the primary end point did not differ significantly between placebo (18 of 28 [64%]; 90% CI, 47%-79%) and either vemircopan group (180 mg: 16 of 28 [57%]; 90% CI, 40%-73%; 120 mg: 8 of 14 [57%]; 90% CI, 33%-79%). No significant differences were observed for the secondary end points. No cases of meningococcal infection were reported; 1 participant died due to hepatic failure and 1 discontinued study treatment due to herpes simplex meningitis. CONCLUSIONS AND RELEVANCE: In this double-blind, parallel-group, placebo-controlled phase 2 randomized clinical trial, vemircopan did not meet the prespecified threshold for efficacy, and consequently, the study was terminated. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05218096.
引用
- Saccà F, Gialdini G, Howard JF, et al. Efficacy and Safety of Vemircopan in Generalized Myasthenia Gravis: A Randomized Clinical Trial. JAMA Neurol. 2026. PMID: 42043793. doi:10.1001/jamaneurol.2026.0902
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。